Semaglutide denied as non-formulary by Aetna?

Aetna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Semaglutide as Non-Formulary

Semaglutide is a branded specialty drug, and Aetna plan formularies vary widely across employer groups and marketplace plans. A non-formulary denial means the specific semaglutide product — whether prescribed for diabetes or weight management — is not listed on the member's plan formulary at a covered tier, or is excluded entirely for a particular indication (notably, many employer plans exclude weight-loss medications as a benefit category). Understanding which situation applies determines your best strategy.

## Why This Denial Is Appealable

If the non-formulary status stems from a missing formulary listing and a formulary alternative exists but is clinically inappropriate for you, a formulary exception is your first remedy. If the entire benefit category is excluded (for example, weight-loss drugs excluded by plan design), the exception path is narrower — but the denial may still be appealable if the drug is being used for a covered indication (such as diabetes) and was miscategorized. Confirm the basis for the denial before choosing your approach.

## Your Federal Appeal Rights

• Formulary exception request: If a formulary alternative exists but is clinically inappropriate, your prescriber must document why. File this alongside or immediately after the denial.
• Internal appeal: If the exception is denied, file a formal internal appeal. Aetna must explain the specific formulary criteria applied.
• ACA §2719 / External Review: After an adverse internal decision, most commercial and marketplace plans must offer independent external review. You generally have approximately four months from the denial notice.
• ERISA §503 (employer plans): Entitles you to the full claim file and written denial reasoning. Note: ERISA plans are not required to cover specific drugs or benefit categories, so if the exclusion is a plan-design decision, external review may have limited scope — confirm with an attorney or patient advocate.
• Expedited review: Available when delay poses a clinical risk.

## Appeal Timeline

1. Obtain the denial letter and confirm whether the issue is (a) formulary tier placement, (b) formulary alternative availability, or (c) a benefit-category exclusion. 2. For tier/alternative issues, file a formulary exception immediately with prescriber support. 3. For benefit-exclusion issues, confirm whether the drug is being used for a separately covered indication. 4. Escalate to external review if internal appeal fails.

## Documentation to Gather

• Formulary alternative trial history: For each drug Aetna identifies as a formulary alternative, provide chart-documented trial history with dates, outcomes, and reasons for failure or contraindication.
• Prescriber exception letter: Addressing each formulary alternative and explaining why semaglutide is the medically necessary choice for this patient.
• Indication clarification: If semaglutide is prescribed for a covered indication (e.g., diabetes) and was denied under a weight-loss exclusion, document the primary diagnosis clearly.
• Diagnosis and clinical records: Supporting the specific indication for which semaglutide is prescribed.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria for the relevant drug class. Create a table matching each exception criterion to the corresponding clinical documentation. If the denial involves a benefit-category exclusion, include a clear statement of the primary diagnosis and the relevant coverage provision to clarify the categorization.